Abstract
1 Servei de Microbiologia, Centre de Diagnòstic Biomèdic, Hospital Clínic, IDIBAPS, Facultat de Medicina, Universitat de Barcelona, Villarroel 170, 08036 Barcelona, Spain
2 Unitat de Microbiologia, Departament de Ciències Mèdiques Bàsiques, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Sant Llorenç 21, 43201 Reus, Spain
3 Unidad de Microbiología, Hospital Royo Villanova, Avda San Gregorio 30, 59915 Zaragoza, Spain
Resistance to β-lactams is a potential problem for the therapeutic management of extraintestinal diseases, especially when dealing with species such as A. veronii biovar sobria, which has been implicated in important life-threatening infections (Figueras, 2005; Ouderkirk et al., 2004; Shiina et al., 2004). The genetic profiles of β-lactamases of this species have been well characterized (Stunt et al., 1998; Walsh et al., 1997), as has its ability to produce three enzymes, a Bush group 2d penicillinase, a group 1 cephalosporinase and a metallo-β-lactamase (ImiS) (Tsai et al., 2006), which are all chromosome-encoded, inducible (Ko et al., 1998) and co-regulated by a common pathway (Alksne & Rasmussen, 1997; Walsh et al., 1995). This ImiS metallo-β-lactamase belongs to the molecular class B or group 3 and is 98 % identical to CphA, a metallo-β-lactamase found in A. hydrophila (Hernandez Valladares et al., 2000). ImiS is a monomeric enzyme able to hydrolyse carbapenems such as imipenem and meropenem but with poor activity against other β-lactams (Walsh et al., 1996, 1998).
Despite the extensive work performed on carbapenem resistance mediated by chromosomally located carbapenemases in Aeromonas species, carbapenem-resistant A. veronii biovar sobria isolates selected in clinical practice have not been described to our knowledge. In the present study, we report the in vivo development of imipenem resistance in isolates of A. veronii biovar sobria recovered from bile samples of a patient with cholangitis. The emergence of imipenem resistance was associated with overexpression of the imiS gene.
Patient. The patient was an 88-year-old woman with a history of diabetes mellitus, hypertension and Alzheimer's disease, admitted to hospital from 13 to 18 June 2007 due to a severe urinary tract infection. She was directly treated intravenously (i.v.) with ciprofloxacin (two doses of 200 mg). Treatment was changed to amoxicillin–clavulanic acid (1 g every 8 h i.v.) on days 2 and 3, and an oral treatment (875/125 g) with the same antibiotic was established on days 4 and 5. No cultures were performed. The patient was released and instructed to complete the same treatment up to 15 days (until 30 June). The patient was again admitted on 4 July with signs of general malaise, vomiting, fever and altered mental state. Physical examination revealed jaundice and hypotension. Blood tests showed hyperglycaemia, leukocytosis, hyperbilirubinaemia and increased alkaline phosphatase concentration (490.6 IU l–1, normal rate 45–122 IU l–1). Abdominal ultrasonography revealed the presence of stones in the bile ducts and cholecystitis. A laparoscopic cholecystectomy and bile duct clearance were performed and a pig-tail catheter was placed. The patient was diagnosed with acute cholelithiasis secondary to choledocolithiasis, and remained in the hospital for 20 days. She was initially treated for 2 days with amoxicillin plus clavulanic acid, but treatment was changed for 10 days to piperacillin–tazobactam on confirmation of the diagnosis. A first bile sample was obtained on placement of the pig-tail catheter and the second was collected from the biliary drainage 5 days later. Both samples were processed on solid and in liquid media. Nine oxidase-positive isolates with different colony morphologies and phenotypic characteristics (three from the first sample and six from the second) were identified with API 20E (bioMérieux) as A. hydrophila.The isolates were sent to two different reference laboratories for further studies. The nine isolates were identified on the basis of the 16S rDNA-RFLP (Figueras et al., 2000b).
Susceptibility testing. Antimicrobial susceptibility was determined twice at two different laboratories using different methods: (i) MicroScan Combo Gramnegative panels (Dade MicroScan); (ii) the Kirby–Bauer method to test the susceptibility to ampicillin and cephalothin following the Clinical and Laboratory Standards Institute criteria (CLSI, 2006). The MIC of imipenem was also determined in the absence and the presence of 10 mM EDTA by Etest (Biodisk).
Molecular typing. To elucidate the epidemiological relationship of these strains, the nine isolates were genotyped at two different laboratories using chromosomal DNA analysis by digestion with low frequency restriction enzymes and then PFGE and enterobacterial repetitive intergenic consensus PCR (ERIC-PCR) following the conditions previously described (Gallardo et al., 1999; Soler et al., 2003).
RT-PCR. The RNA was purified free of DNA and RT-PCR was performed following the procedure previously described (Ruiz et al., 2007). The primers used to amplify a 400 bp region of the imiS gene were ImiS-1 (5'-GTCTATTTCGGGGCCAAGGGAGTG-3') and ImiS-2 (5'-GCTGGTCGGGGAAGTAAACAAAGA-3'). As an internal control for the reaction, the 16S rRNA gene was used. The primers used to amplify this gene were 8F (5'-AGAGTTTGATCCTGGCTCAG-3') and 806R (5'-GGACTACCAGGGTATCTAAT-3') amplifying a region of 798 bp. After several trials, the final number of cycles was 16 for each of the two genes.
The isolates were genetically and biochemically identified as A. veronii biovar sobria. Both typing methods, PFGE and ERIC-PCR, demonstrated that the nine isolates had identical patterns, confirming that they belonged to the same clone (Fig. 1). The antimicrobial susceptibility patterns are illustrated in Table 1. The nine clinical isolates were susceptible to ciprofloxacin, showing a MIC lower than 0.125 µg ml–1. All the isolates except 767-4 and 767-6 with MICs lower than 4 µg ml–1 were resistant to ampicillin. This is an interesting finding since most Aeromonas species, with the exception of a few strains and Aeromonas trota, are resistant to ampicillin (Maluping et al., 2005; Abbott et al., 2003). Overall, a low reproducibility and changeable susceptibility were observed for almost all β-lactam antibiotics with the exception of aztreonam and cefotaxime. The susceptibility of the isolates to cephalothin was also variable, with isolates 459-1, 459-2, 767-1, 767-2, 767-3 and 767-5 showing resistance to this antimicrobial agent. In fact, susceptibility to the latter antibiotic is one of the specific characteristics of A. veronii biovar sobria (Abbott et al., 2003); therefore, the variability observed compromises the classical use of this phenotypic character for species delineation (Abbott et al., 2003). Seven isolates were also resistant to imipenem (459-2, 767-1, 767-2, 767-3, 767-4, 767-5 and 767-6) with MICs of 32 µg ml–1. In the presence of 10 mM EDTA, the MIC of imipenem decreased to <1.0 µg ml–1, suggesting the implication of a metallo-β-lactamase in the resistance to imipenem. Resistance to the latter drug is not uncommon. In a recent study on Aeromonas bacteraemia in patients with haematological malignancies, 35.6 % of the strains were found to be resistant to imipenem (Tsai et al., 2006).
|
Table 1. MICs (µg ml–1) of different antibacterial agents for A. veronii biovar sobria
Isolates 459-1 and 767-5 were selected to analyse the role of the imiS gene in the resistance to imipenem. The imipenem-resistant isolate 767-5 showed a greater expression of the imiS gene when compared to the expression in the imipenem-susceptible isolate 459-1 (Fig. 2). Meanwhile, the expression of the 16S rRNA gene was equivalent in both isolates. This imipenem-resistant isolate demonstrated overproduction of ImiS and showed a resistant phenotype also characterized by resistance to cephalotin, suggesting an overexpression of the chromosomal cephalosporinase. In fact, the three chromosomally located β-lactamases found in A. veronii biovar sobria are simultaneously overexpressed in mutants (Walsh et al., 1995).
|
Aeromonas species have been involved in a broad spectrum of human infections (Figueras, 2005; Janda & Abbot, 1998). It has been reported that this group of bacteria has been implicated in 12 % of hepatobiliary infections, among which the most common is cholangitis (Figueras, 2005; Janda & Abbot, 1998; Clark & Chenoweth, 2003). Previous cases of acute cholecystitis produced by A. veronii without septicaemia, as in our patient, as well as bacteraemia secondary to biliary tract infection have been described (Figueras, 2005; Maluping et al., 2005). It has been speculated that primary undiagnosed biliary infection may induce Aeromonas septicaemia (Maluping et al., 2005).
The emergence of resistance among Aeromonas species has been accelerated by the clinical use of antibiotics. To our knowledge, carbapenem-resistant A. veronii biovar sobria strains selected in clinical practice have not been reported to date. In the present study, we have shown the presence of several imipenem-susceptible and -resistant A. veronii biovar sobria isolates that belonged to the same clone in bile samples of a patient with cholangitis. This fact led us to consider that the development of resistance to imipenem in this patient was probably due to the antimicrobial pressure over the original imipenem-susceptible bacteria. As in our study, acquired resistance to tetracycline and fluoroquinolone has recently been demonstrated in strains of Aeromonas, possibly associated with antimicrobial therapy (Maluping et al., 2005). These results should make clinicians aware of the possible emergence of multidrug-resistant A. veronii biovar sobria, which, in our study, is probably a consequence of previous treatment of urinary tract infection with amoxicillin plus clavulanic acid.
This work has been supported by grants from the Fundació Ciència i Salut and from the Spanish Ministry of Health (FIS 03/1183 to M. J. F.) and also supported by grant SGR050444 from the Departament d'Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya, Spain, and from the Spanish Ministry of Health (FIS 04/0068 to J. V.).References
Alksne, L. E. & Rasmussen, B. A. (1997). Expression of the AsbA1, OXA-12, and AsbM1 beta-lactamases in Aeromonas jandaei AER 14 is coordinated by a two-component regulon. J Bacteriol 179, 2006–2013.
Clark, N. M. & Chenoweth, C. E. (2003). Aeromonas infection of the hepatobiliary system: report of 15 cases and review of the literature. Clin Infect Dis 37, 506–513.[CrossRef][Medline]
Clinical and Laboratory Standards Institute (2006). Performance Standards for Antimicrobial Susceptibility Testing; 16th Informational Supplement. M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute.
Figueras, M. J. (2005). Clinical relevance of Aeromonas. Rev Med Microbiol 16, 145–153.
Figueras, M. J., Guarro, J. & Martínez-Murcia, A. J. (2000a). Clinically relevant Aeromonas species. Clin Infect Dis 30, 988–989.[Medline]
Figueras, M. J., Soler, L., Chacón, M. R., Guarro, J. & Martinez-Murcia, A. J. (2000b). Extended method for discrimination of Aeromonas spp. by 16S rDNA RFLP analysis. Int J Syst Evol Microbiol 50, 2069–2073.[Abstract]
Gallardo, F., Ruiz, J., Marco, F., Towner, K. J. & Vila, J. (1999). Increase in incidence of resistance to ampicillin, chloramphenicol and trimethoprim in clinical isolates of Salmonella serotype Typhimurium with investigation of molecular epidemiology and mechanisms of resistance. J Med Microbiol 48, 367–374.
Hernandez Valladares, M., Kiefer, M., Heinz, U., Soto, R. P., Meyer-Klaucke, W., Nolting, H. F., Zeppezauer, M., Galleni, M., Frere, J. M. & other authors (2000). Kinetic and spectroscopic characterization of native and metal-substituted β-lactamase from Aeromonas hydrophila. FEBS Lett 467, 221–225.[CrossRef][Medline]
Janda, J. M. & Abbot, S. L. (1998). Evolving concepts regarding the genus Aeromonas: an expanding panorama of species, disease presentations, and unanswered questions. Clin Infect Dis 27, 332–334.[Medline]
Ko, W. C., Yu, K. W., Liu, C. Y., Huang, C. T., Leu, H. S. & Chuang, Y. C. (1996). Increasing antibiotic resistance in clinical isolates of Aeromonas strains in Taiwan. Antimicrob Agents Chemother 40, 1260–1262.
Ko, W. C., Wu, H. M., Chang, T. C., Yan, J. J. & Wu, J. J. (1998). Inducible β lactam resistance in Aeromonas hydrophila: therapeutic challenge for antimicrobial therapy. J Clin Microbiol 36, 3188–3192.
Ko, W. C., Chiang, S. R., Lee, H. C., Tang, H. J., Wang, Y. Y. & Chuang, Y. C. (2003). In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila. Antimicrob Agents Chemother 47, 2217–2222.
Koehler, J. M. & Ashdown, L. R. (1993). In vitro susceptibilities of tropical strains of Aeromonas species from Queensland, Australia, to 22 antimicrobial agents. Antimicrob Agents Chemother 37, 905–907.
Maluping, R. P., Lavilla-Pitogo, C. R., DePaola, A., Janda, J. M., Krovacek, K. & Greko, C. (2005). Antimicrobial susceptibility of Aeromonas spp., Vibrio spp. and Plesiomonas shigelloides isolated in the Philippines and Thailand. Int J Antimicrob Agents 25, 348–350.[CrossRef][Medline]
Mencacci, A., Cenci, E., Mazzolla, R., Farinelli, S., D'Alo, F., Vitali, M. & Bistoni, F. (2003). Aeromonas veronii biovar veronii septicaemia and acute suppurative cholangitis in a patient with hepatitis B. J Med Microbiol 52, 727–730.
Ouderkirk, J. P., Bekhor, D., Turett, G. S. & Murali, R. (2004). Aeromonas meningitis complicating medicinal leech therapy. Clin Infect Dis 38, e36–e37.[CrossRef][Medline]
Rossolini, G. M., Walsh, T. & Amicosante, G. (1996). The Aeromonas metallo-beta-lactamases: genetics, enzymology, and contribution to drug resistance. Microb Drug Resist 2, 245–252.[Medline]
Ruiz, M., Martí, S., Fernandez-Cuenca, F., Pascual, A. & Vila, J. (2007). High prevalence of carbapenem-hydrolysing oxacillinases in epidemiologically related and unrelated Acinetobacter baumannii clinical isolates in Spain. Clin Microbiol Infect 13, 1192–1198.[CrossRef][Medline]
Sader, H. S. & Jones, R. N. (2005). Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 25, 95–109.[CrossRef][Medline]
Shiina, Y., Ii, K. & Iwanaga, M. (2004). An Aeromonas veronii biovar sobria infection with disseminated intravascular gas production. J Infect Chemother 10, 37–41.[CrossRef][Medline]
Soler, L., Figueras, M. J., Chacón, M. R., Guarro, J. & Martinez-Murcia, A. J. (2003). Comparison of three molecular methods for typing Aeromonas popoffii isolates. Antonie van Leeuwenhoek 83, 341–349.[CrossRef][Medline]
Stunt, R. A., Amyes, A. K., Thomson, C. J., Payne, D. J. & Amyes, S. G. (1998). The production of a novel carbapenem-hydrolysing beta-lactamase in Aeromonas veronii biovar sobria, and its association with imipenem resistance. J Antimicrob Chemother 42, 835–836.
Tsai, M. S., Kuo, C. Y., Wang, M. C., Wu, H. C., Chien, C. C. & Liu, J. W. (2006). Clinical features and risk factors for mortality in Aeromonas bacteremic adults with hematologic malignancies. J Microbiol Immunol Infect 39, 150–154.[Medline]
Vila, J., Marco, F., Soler, L., Chacon, M. & Figueras, M. J. (2002). In vitro antimicrobial susceptibility of clinical isolates of Aeromonas caviae, Aeromonas hydrophila and Aeromonas veronii biotype sobria. J Antimicrob Chemother 49, 701–702.
Vila, J., Ruiz, J., Gallardo, F., Martha, V., Lara, S., Figueras, M. J. & Gascon, J. (2003). Aeromonas spp. and traveler's diarrhea: clinical features and antimicrobial resistance. Emerg Infect Dis 9, 552–555.[Medline]
Walsh, T. R., Payne, D. J., MacGowan, A. P. & Bennett, P. M. (1995). A clinical isolate of Aeromonas sobria with three chromosomally mediated inducible β-lactamases: a cephalosporinase, a penicillinase and a third enzyme, displaying carbapenemase activity. J Antimicrob Chemother 35, 271–279.
Walsh, T. R., Gamblin, S., Emery, D. C., MacGowan, A. P. & Bennett, P. M. (1996). Enzyme kinetics and biochemical analysis of ImiS, the metallo-β-lactamase from Aeromonas sobria 163a. J Antimicrob Chemother 37, 423–431.
Walsh, T. R., Neville, W. A., Haran, M. H., Tolson, D., Payne, D. J., Walsh, T. R., Stunt, R. A., Nabi, J. A., MacGowan, A. P. & Bennett, P. M. (1997). Distribution and expression of beta-lactamase genes among Aeromonas spp. J Antimicrob Chemother 40, 171–178.
Walsh, T. R., Neville, W. A., Haran, M. H., Tolson, D., Payne, D. J., Bateson, J. H., MacGowan, A. P. & Bennett, P. M. (1998). Nucleotide and amino acid sequences of the metallo-β-lactamase, ImiS, from Aeromonas veronii bv. sobria. Antimicrob Agents Chemother 42, 436–439.